EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC 4.0

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long‐Acting FGF21 Analog Zalfermin

Kirsten Dahl iD, Martin Haljeta Friedrichsen, Rasmus Ribel-Madsen, Jakob Schiøler Hansen, Jesper Ole Clausen, Mads Axelsen, Mads Sundby Palle iD, Solvej Lund Lippert, Olle Björkdahl, Søren Toubro, Cassandra Key, Birgitte Andersen

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70435 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Kirsten Dahl und 11 weiteren Autor:innen. Beteiligte Einrichtung: Novo Nordisk A/S, Bagsværd, Denmark. Hauptthemen laut MEDLINE: Fibroblast Growth Factors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This first‐in‐human study investigated the safety, pharmacokinetics, and pharmacodynamics of the long‐acting fibroblast growth factor 21 (FGF21) analog zalfermin. Healthy male participants ( n = 56) with body mass index 25.0–34.9 kg/m 2 were randomized to single ascending doses (2, 6, 12, 24, 48, 96, and 180 mg) of subcutaneous zalfermin or placebo. In a second study, a single dose of 12, 30, or 96 mg was administered to Japanese ( n = 24) and non‐Asian ( n = 18) healthy males to confirm a consistent safety and pharmacokinetic profile across ethnicity. Overall, 98 participants were enrolled across both studies and followed for 36 days. Blood samples were obtained for safety and for pharmacokinetic and pharmacodynamic assessments. The primary endpoint for both studies was the number of adverse events from treatment initiation to the end of follow‐up, which was greater in the highest zalfermin dose cohorts in both studies. Adverse events were non‐serious, mainly gastrointestinal‐related, and mostly mild to moderate in severity; no deaths occurred. In both studies, dose proportionality was established for maximum serum concentration and area under the curve from time 0 to infinity. Time to maximum serum concentration ranged from 24 to 54 h. The serum half‐life of zalfermin was ~120 h in both studies, compatible with once‐weekly dosing. Significant improvements in plasma lipids were observed. Zalfermin had an acceptable safety profile across all single ascending doses, consistent with the FGF21 class. Further investigations into multiple ascending doses of zalfermin and treatment duration are warranted to assess the potential treatment of steatohepatitis and cardiometabolic disease. Trial Registration: ClinicalTrials.gov (NCT03015207 and NCT04722653)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fibroblast Growth FactorsHumansMaleAdultYoung AdultMiddle AgedDose-Response Relationship, DrugHealthy VolunteersDouble-Blind MethodInjections, Subcutaneous

Stichwörter der Autor:innen

adverse drug reactionsadverse eventsethnicitylivermetabolismobesitypharmacodynamicspharmacokineticspharmacologyphase I

Substanzen

Fibroblast Growth FactorsFGF21 protein, humanfibroblast growth factor 21

Autor:innen und Institutionen

  • Novo Nordisk A/S, Bagsværd, Denmark.
  • Gubra A/S, Hørsholm, Denmark.
  • ICON Early Phase Service, San Antonio, Texas, USA.

ORCID-Profile: Kirsten Dahl, Mads Sundby Palle

Zitieren

APA

Dahl, K., Friedrichsen, M. H., Ribel-Madsen, R., Hansen, J. S., Clausen, J. O., Axelsen, M., Palle, M. S., Lippert, S. L., Björkdahl, O., Toubro, S., Key, C., & Andersen, B. (2025). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long‐Acting FGF21 Analog Zalfermin. Clinical and Translational Science. https://doi.org/10.1111/cts.70435

Vancouver

Dahl K, Friedrichsen MH, Ribel-Madsen R, Hansen JS, Clausen JO, Axelsen M, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long‐Acting FGF21 Analog Zalfermin. Clinical and Translational Science. 2025. doi:10.1111/cts.70435

BibTeX
@article{Dahl2025,
  author = {Dahl, Kirsten and Friedrichsen, Martin Haljeta and Ribel-Madsen, Rasmus and Hansen, Jakob Schiøler and Clausen, Jesper Ole and Axelsen, Mads and Palle, Mads Sundby and Lippert, Solvej Lund and Björkdahl, Olle and Toubro, Søren and Key, Cassandra and Andersen, Birgitte},
  title = {Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long‐Acting FGF21 Analog Zalfermin},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70435}
}
Kostenlos starten →